Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways [PDF]
, 2009 Xiaohai Li +4 more
openalex +1 more source
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib [PDF]
, 2009 David Masiello +2 more
openalex +1 more source
Dasatinib‐induced loss of eyebrows [PDF]
British Journal of Haematology, 2017 openaire +3 more sources
Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplatin [PDF]
, 2009 Paolo Ceppi +10 more
openalex +1 more source
Inhibition of immune responses by Dasatinib may account for its different effects on neuroblastoma between in vitro and in vivo [PDF]
, 2009 Jiezhong Chen
openalex +1 more source
Imaging the Binding Between Dasatinib and Its Target Protein in Living Cells Using an SLP Tag System on Intracellular Compartments. [PDF]
Int J Mol SciPark DK +4 more
europepmc +1 more source
Dasatinib Dose Optimization Based on Therapeutic Drug Monitoring in Patients with Chronic-Phase Chronic Myeloid Leukemia. [PDF]
Drug Des Devel TherCheng F +5 more
europepmc +1 more source
Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases [PDF]
, 2010 Lina Han +3 more
openalex +1 more source
Siglec6 CAR T cells suppressed progression of AML via inhibiting Siglec6 and SHP2 induced Src and ERK signaling activation. [PDF]
Sci RepLi Q +9 more
europepmc +1 more source